Pharmacokinetics is a branch of pharmacology that studies the fate of substances such as new pharmaceutical compounds administered externally to a living organism and is divided into many aspects including the profiling of the extent of absorption, distribution, metabolism and excretion (ADME). While in vitro ADME assays provide valuable insight into the discovery of new drugs, drug discovery research still requires the use of in vivo pharmacokinetics studies when evaluating a molecule for its pharmaceutical properties. This is because one of the primary reasons cited for failure of new drug candidates in clinical trials is the lack of a suitable pharmacokinetics profile. Plasma concentration versus time profiles are vital for deriving a more detailed analysis of drug exposure in terms of pharmacokinetics and toxicokinetics. When selecting suitable leads during drug discovery research, it is essential to perform in vivo pharmacokinetics in order to select those compounds that exhibit an appropriate pharmacokinetics profile so as to achieve the desired pharmacological action and to minimize side effects.
NoAb BioDiscoveries is a contract research organization located in the heart of one of North America's key biotech hubs that provides a wide range of specialized and proprietary research services for drug discovery research. This cutting edge research facility helps to shape and optimize drug discovery research by providing superior discovery services that include in vivo pharmacokinetics, in vitro ADME assays, bioanalytical services and gene expression assays. NoAb BioDiscoveries is committed to accelerating the timelines in drug discovery research by using innovation to provide advanced research tools that better characterize the pharmacokinetic properties of new drug candidates. This enables the focus to be on accurate and reliable lead selection and the optimization of the selection of viable clinical candidates for pre-clinical and clinical development. NoAb BioDiscoveries' in vivo pharmacokinetics studies include standard studies in carotid artery and jugular vein catheterized rats with intra-duodenal dosing, carotid artery, jugular vein and bile duct catheterized rats and guinea pigs and hepatoportal vein catheterized rats and specialized techniques that include microdialysis and cerebrospinal fluid and plasma collection in freely moving rats.
Key pharmacokinetic parameters that play a role in selecting the best compounds for further pre-clinical and clinical development include oral bioavailability, plasma clearance, volume of distribution and mean residence time (or plasma half-life). At NoAb BioDiscoveries, the in vivo pharmacokinetics studies allow the generation of early stage pharmacokinetics data in parallel with pharmacological testing enabling early relationships to be examined between exposure and efficacy. Highly trained and experienced scientists conduct all the scientific procedures in-house under strict guidelines using fully conscious animals which have been appropriately cannulated for drug administration and sample collection. The skilled scientists design the best strategies and protocols to suit any drug discovery needs according to customer specifications assuring you get quality, efficient and timely research services. Detailed information on the standard and specialized procedures is available at www.noabbiodiscoveries.com.
NoAb BioDiscoveries continues on the path to offering premier drug discovery services to its clients by using innovation to improve its discovery services. The in vivo pharmacokinetics studies, in vitro ADME assays and gene expression profiling have all been developed to provide rapid, accurate and reliable information that guarantees your success. You enjoy reduced costs and maximized success when you choose NoAb BioDiscoveries for advanced drug discovery services!
